Literature DB >> 1602133

Immunomodulatory effects of transforming growth factor-beta on T lymphocytes. Induction of CD8 expression in the CTLL-2 cell line and in normal thymocytes.

T H Inge1, K M McCoy, B M Susskind, S K Barrett, G Zhao, H D Bear.   

Abstract

We investigated the role of transforming growth factor-beta 1 (TGF-beta) in regulation of T cell growth and differentiation. Treatment of CTLL-2 cells with TGF-beta inhibited IL-2-dependent proliferation and caused morphologic changes as well as increased adherence. A major change of phenotype in TGF-beta-treated cells was the de novo expression of CD8 alpha chain in 35% of cells, which required the continuous presence of TGF-beta. Of the CD8 alpha+ cells, 20 to 30% co-expressed CD8 beta chain. Increased CD8 expression occurred even in the total absence of cell growth, was not a consequence of growth inhibition, and was not a result of selective growth or survival of CD8+ cells. New RNA synthesis was required for TGF beta-induced CD8 alpha surface expression, inasmuch as this was prevented by treatment with actinomycin D. Northern blot analysis demonstrated that cells treated with IL-2 + TGF-beta rapidly accumulated mRNA encoding both chains of the CD8 dimer, to a level fourfold greater than control by 6 to 12 h. In contrast, the IL-2-dependent increases in IL-2R alpha, IL-2R beta, and Granzyme B mRNA levels in these cultures were profoundly inhibited by TGF-beta. When unfractionated murine thymocytes were stimulated with phorbol dibutyrate plus ionomycin and cultured with IL-2 + TGF-beta, an increase in CD8 alpha mRNA was seen and greater numbers of CD8+ cells with higher levels of CD8 alpha and CD8 beta surface expression resulted, as compared to controls treated with IL-2 alone. Furthermore, similar treatment of CD4-CD8-(double negative) thymocytes with TGF-beta induced de novo CD8 alpha expression by a substantial number of cells, and the majority of these CD8+ cells lacked TCR/CD3. These data suggest that TGF-beta has both positive and negative regulatory effects on the expression of gene products important for T lymphocyte differentiation and function.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1602133

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 2.  Gammadelta T cells as immune effectors against high-grade gliomas.

Authors:  Lawrence S Lamb
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

3.  Analysis of the local kinetics and localization of interleukin-1 alpha, tumour necrosis factor-alpha and transforming growth factor-beta, during the course of experimental pulmonary tuberculosis.

Authors:  R Hernandez-Pando; H Orozco; K Arriaga; A Sampieri; J Larriva-Sahd; V Madrid-Marina
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

4.  Inhibitory effects of transforming growth factor-beta (TGF-beta) on certain functions of intraepithelial lymphocytes.

Authors:  E C Ebert
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

5.  Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.

Authors:  Yohei Mineharu; A K M Ghulam Muhammad; Kader Yagiz; Marianela Candolfi; Kurt M Kroeger; Weidong Xiong; Mariana Puntel; Chunyan Liu; Eva Levy; Claudia Lugo; Adrina Kocharian; James P Allison; Michael A Curran; Pedro R Lowenstein; Maria G Castro
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

6.  Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.

Authors:  Nichole L Bryant; Catalina Suarez-Cuervo; G Yancey Gillespie; James M Markert; L Burt Nabors; Sreelatha Meleth; Richard D Lopez; Lawrence S Lamb
Journal:  Neuro Oncol       Date:  2009-02-11       Impact factor: 12.300

7.  Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype.

Authors:  A G Geiser; J J Letterio; A B Kulkarni; S Karlsson; A B Roberts; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

Review 8.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

9.  CD3zeta expression and T cell proliferation are inhibited by TGF-beta1 and IL-10 in cervical cancer patients.

Authors:  Cinthya E Díaz-Benítez; Karla R Navarro-Fuentes; Jacqueline A Flores-Sosa; Janet Juárez-Díaz; Felipe J Uribe-Salas; Edgar Román-Basaure; Ludwig E González-Mena; Patricia Alonso de Ruíz; Guillermina López-Estrada; Alfredo Lagunas-Martínez; Victor H Bermúdez-Morales; Juan M Alcocer-González; Jesús Martínez-Barnetche; Rogelio Hernández-Pando; Yvonne Rosenstein; José Moreno; Vicente Madrid-Marina
Journal:  J Clin Immunol       Date:  2009-03-04       Impact factor: 8.317

10.  Early progression of thymocytes along the CD4/CD8 developmental pathway is regulated by a subset of thymic epithelial cells expressing transforming growth factor beta.

Authors:  Y Takahama; J J Letterio; H Suzuki; A G Farr; A Singer
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.